Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $404.00

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price upped by Citigroup from $364.00 to $404.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also weighed in on ALNY. Wells Fargo & Company boosted their price […]

Leave a Reply

Your email address will not be published.

Previous post AIRO Group (NASDAQ:AIRO) Rating Lowered to “Sell” at Wall Street Zen
Next post Secure Trust Bank’s (STB) “House Stock” Rating Reiterated at Shore Capital